Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTIH Study of GSK3036656 in Healthy Volunteers
NCT03075410Phase 1Completed
- Sponsor
- GSK
- Start
- Apr 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ganfeborole in Tuberculosis (TB) (12 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events (nSAE) and Serious Adverse Events (SAEs) up to 12 weeks, Number of Participants With Abnormal Electrocardiogram (ECG) Findings up to 8 weeks and 11 more. Started Apr 2017; status: completed.
02
Drugs
ganfeborole
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03075410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075410.